A comparative study between injection buprenorphine vs injection dexmedetomidine with 0.375 percent ropivacaine in transversus abdominis plane block for postoperative pain relief in elective gynecological laparotomy patients.

A comparative study between injection buprenorphine hydrochloride versus injection dexmedetomidine with injection 0.375 percentage ropivacaine in transversus abdominus plane block for postoperative analgesia in patients undergoing elective gynecological exploratory laparotomy procedures: a randomized double-blind controlled study. - nil

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/06/087998

Enrollment

Registered

2025-06-02

Start date

Unknown

Completion date

Unknown

Last updated

2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D279- Benign neoplasm of unspecified ovary Health Condition 2: N800- Endometriosis of uterus Health Condition 3: D259- Leiomyoma of uterus, unspecified Health Condition 4: C569- Malignant neoplasm of unspecifiedovary Health Condition 5: C55- Malignant neoplasm of uterus, partunspecified

Interventions

Intervention1: Injection Buprenorphine Hydrochloride with Injection Ropivacaine.: Injection Buprenorphine hydrochloride 0.5 ml (150 microgram) with 20ml of 0.375% ropivacaine to be administered in bil

Eligibility

Inclusion criteria

Inclusion criteria: ASA I and ASA II, age between 20-60 years, female, BMI-24to 35 kg/m2, elective gynecological laparotomy surgery.

Exclusion criteria

Exclusion criteria: patient refusal, known hypersensitivity to local anesthetics, BMI greater than 35kg/m2, psychiatric or physical illness leading to debility or inability to cooperate, history of coagulopathy or bleeding diasthesis, opioid dependence, infection at injection site, NYHA greater than class2, chronic pain.

Design outcomes

Primary

Measure	Time frame
Comparison of duration of analgesia between the study drugs.Timepoint: Duration of analgesia will be calculated from the time of tranversus abdominis plane block administration with the study drug until there is requirement of administration of first rescue analgesic when the patient complains of pain. This time period from administration of study drug till the patient complains of pain will be the duration of analgesia provided by the study drug.	—

Measure

Time frame

Comparison of duration of analgesia between the study drugs.Timepoint: Duration of analgesia will be calculated from the time of tranversus abdominis plane block administration with the study drug until there is requirement of administration of first rescue analgesic when the patient complains of pain. This time period from administration of study drug till the patient complains of pain will be the duration of analgesia provided by the study drug.

—

Secondary

Measure	Time frame
Comparison of quality of analgesia based on VAS (visual analog score), hemodynamic parameters, side-effects if any between the study groups.Timepoint: Quality of analgesia, hemodynamic parameters, side effects between the study groups will be assessed in postoperative period at 1st,2nd,4th,6th,8th,12th, 18th & 24th hours respectively.	—

Countries

India

Contacts

Public ContactDR DEBASHISH MONDAL

IPGMER and SSKM Hospital

dmondal2005@gmail.com8777854338

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026